Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity

Nature Reviews Cardiology

Volumn 7, Issue 7, 2010, Pages 376-383

  Wazni, Oussama ^a   Wilkoff, Bruce L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; PLACEBO; PSEUDOMONIC ACID; VANCOMYCIN;

ANTIBIOTIC THERAPY; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DEFIBRILLATION; DEFIBRILLATOR; FOLLOW UP; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTATION; MONITORING; MORBIDITY; PHYSICIAN ATTITUDE; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; SHOCK; STAPHYLOCOCCUS INFECTION; TACHYCARDIA; TREATMENT INDICATION;

CLINICAL COMPETENCE; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; HEART FAILURE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; PROSTHESIS-RELATED INFECTIONS; TELEMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954175839     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.50     Document Type: Review

References (90)

1. Epstein, A. E. et al. ACC/AHA/HrS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. Heart Rhythm 5, 934-955 (2008).
2. Estes, N. A. M. III & Lindsay, B. D. for the Heart rhythm Society. Letter detailing the current recommended training curriculum for the clinical use of cardiovascular implantable electronic devices [online], http://www.hrsonline.org/ Policy/ClinicalGuidelines/upload/ revised-ATP-Letter- 10-29.pdf (2008).
3. Naccarelli, G. v., Conti, J. B. & Tracy, C. M. for the Heart rhythm Society. Task Force 6: Training in specialized electrophysiology, cardiac pacing, and arrhythmia management [online], http://www.hrsonline.org/Policy/ ClinicalGuidelines/upload/ Task-Force-6-COCATS-3.pdf (2008).
4. Curtis, J. P. et al. Association of physician certification and outcomes among patients receiving an implantable cardioverterdefibrillator. JAMA 301, 1661-1670 (2009).
5. Hammill, S., Phurrough, S. & Brindis, r. The National ICD registry: now and into the future. Heart Rhythm 3, 470-473 (2006).
6. Al-Khatib, S. M. et al. Patient and implanting physician factors associated with mortality and complications following implantable cardioverterdefibrillator implantation, 2002-2005. Circ. Arrhythm. Electrophysiol. 1, 240-249 (2008).
7. Aggarwal, r. K., ramsdale, D. r. & Charles, r. G. Antibiotic prophylaxis in permanent pacemaker implantation. Br. Heart J. 73, 392 (1995).
8. Bluhm, G., Jacobson, B. & ransjo, U. Antibiotic prophylaxis in pacemaker surgery: a prospective trial with local or systemic administration of antibiotics at generator replacements. Pacing Clin. Electrophysiol. 8, 661-670 (1985).
9. Bluhm, G., Nordlander, r. & ransjo, U. Antibiotic prophylaxis in pacemaker surgery: a prospective double blind trial with systemic administration of antibiotic versus placebo at implantation of cardiac pacemakers. Pacing Clin. Electrophysiol. 9, 720-726 (1986).
10. Da Costa, A. et al. Antibiotic prophylaxis for permanent pacemaker implantation: a metaanalysis. Circulation 97, 1796-1801 (1998).
11. Gastinger, I. & Herwig, H. [Perioperative preventive use of antibiotics in cardiac pacemaker surgery]. [German] Zentralbl Chir. 113, 465-467 (1988).
12. Glieca, F. et al. [The role of antibiotic prophylaxis in the implantation of pacemakers]. [Italian] Minerva Cardioangiol. 35, 549-552 (1987).
13. Midtvedt, K. & Myrvang, B. [Antibiotic prevention in permanent pacemaker implantation in Norway]. [Norwegian] Tidsskr Nor Laegeforen. 111, 1106-1107 (1991).
14. Morito, N. et al. Orally administered levofloxacin as prophylaxis against pacemaker infection. Exp. Clin. Cardiol. 11, 21-24 (2006).
15. Mounsey, J. P. et al. Antibiotic prophylaxis in permanent pacemaker implantation: a prospective randomised trial. Br. Heart J. 72, 339-343 (1994).
16. Muers, M. F., Arnold, A. G. & Sleight, P. Prophylactic antibiotics for cardiac pacemaker implantation. A prospective trail. Br. Heart J. 46, 539-544 (1981).
17. ramsdale, D. r. et al. Antibiotic prophylaxis for pacemaker implantation: a prospective randomized trial. Pacing Clin. Electrophysiol. 7, 844-849 (1984).
18. Ucchino, S. et al. [Antibiotic prophylaxis in the implantation of permanent pacemakers]. [Italian] Minerva Med. 73, 3181-3184 (1982).
19. de Oliveira, J. C. et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ. Arrhythm. Electrophysiol. 2, 29-34 (2009).
20. Chua, J. D. et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann. Intern. Med. 133, 604-608 (2000).
21. Jog, S. et al. Impact of preoperative screening for methicillin-resistant Staphylococcus aureus by real-time polymerase chain reaction in patients undergoing cardiac surgery. J. Hosp. Infect. 69, 124-130 (2008).
22. Tom, T. S., Kruse, M. W. & reichman, r. T. Update: methicillin-resistant Staphylococcus aureus screening and decolonization in cardiac surgery. Ann. Thorac. Surg. 88, 695-702 (2009).
23. Trautmann, M., Stecher, J., Hemmer, W., Luz, K. & Panknin, H. T. Intranasal mupirocin prophylaxis in elective surgery. A review of published studies. Chemotherapy 54, 9-16 (2008).
24. Arias, M. A., Puchol, A., Castellanos, E. & Pachon, M. The Sprint Fidelis implantable cardioverter-defibrillator (ICD) leads (Medtronic, Inc., Minneapolis, MN, USA) were removed from the market in October 2007 because of the rate of pace-sense conductor fractures. Heart Rhythm 6, e6-e7 (2009).
25. Hauser, r. G. & Hayes, D. L. Increasing hazard of Sprint Fidelis implantable cardioverterdefibrillator lead failure. Heart Rhythm 6, 605-610 (2009).
26. Hauser, r. G., Kallinen, L. M., Almquist, A. K., Gornick, C. C. & Katsiyiannis, W. T. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 4, 892-896 (2007).
27. Danik, S. B. et al. Increased incidence of subacute lead perforation noted with one implantable cardioverter-defibrillator. Heart Rhythm 4, 439-442 (2007).
28. Ellis, C. r. & rottman, J. N. Increased rate of subacute lead complications with small-caliber implantable cardioverter-defibrillator leads. Heart Rhythm 6, 619-624 (2009).
29. Farwell, D., Green, M. S., Lemery, r., Gollob, M. H. & Birnie, D. H. Accelerating risk of Fidelis lead fracture. Heart Rhythm 5, 1375-1379 (2008).
30. Henrikson, C. A. The Sprint Fidelis story: where are we now? Heart Rhythm 6, 611-612 (2009).
31. Kallinen, L. M. et al. Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 5, 775-779 (2008).
32. Kenigsberg, D. N. et al. Sensing failure associated with the Medtronic Sprint Fidelis defibrillator lead. J. Cardiovasc. Electrophysiol. 19, 270-274 (2008).
33. Krahn, A. D. et al. Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: a report from the Canadian Heart rhythm Society Device Advisory Committee. Heart Rhythm 5, 639-642 (2008).
34. Epstein, A. E. et al. Performance of the St Jude Medical riata leads. Heart Rhythm 6, 204-209 (2009).
35. Wilkoff, B. L. Lead failures: dealing with even less perfect. Heart Rhythm 4, 897-899 (2007).
36. Maisel, W. H. et al. recommendations from the Heart rhythm Society Task Force on Lead Performance Policies and Guidelines: developed in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 6, 869-885 (2009).
37. Wilkoff, B. L. et al. Transvenous lead extraction: Heart rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm 6, 1085-1104 (2009).
38. Gould, P. A. et al. Outcome of advisory implantable cardioverter- defibrillator replacement: one-year follow-up. Heart Rhythm 5, 1675-1681 (2008).
39. Watson, W. The Medtronic Lead Integrity Alert (LIA) significantly increases the likelihood of detecting a potential defibrillation lead fracture that could result in inappropriate therapy. Heart Rhythm 6, e7 (2009).
40. Magney, J. Pacemaker or defibrillator lead implantation. Pacing Clin. Electrophysiol. 19, 1400-1401 (1996).
41. Magney, J. E. Anatomical mechanisms that cause lead and catheter damage. Pacing Clin. Electrophysiol. 19, 257-258 (1996).
42. roelke, M. et al. Subclavian crush syndrome complicating transvenous cardioverter defibrillator systems. Pacing Clin. Electrophysiol. 18 (5 Pt 1), 973-979 (1995).
43. Belott, P. How to access the axillary vein. Heart Rhythm 3, 366-369 (2006).
44. de Cock, C. C., Giudici, M. C. & Twisk, J. W. Comparison of the haemodynamic effects of right ventricular outflow-tract pacing with right ventricular apex pacing: a quantitative review. Europace 5, 275-278 (2003).
45. Gold, M. r., Brockman, r., Peters, r. W., Olsovsky, M. r. & Shorofsky, S. r. Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 85, 1106-1109 (2000).
46. Tse, H. F. et al. Functional abnormalities in patients with permanent right ventricular pacing: the effect of sites of electrical stimulation. J. Am. Coll. Cardiol. 40, 1451-1458 (2002).
47. Tantengco, M. v., Thomas, r. L. & Karpawich, P. P. Left ventricular dysfunction after long-term right ventricular apical pacing in the young. J. Am. Coll. Cardiol. 37, 2093-2100 (2001).
48. Wilkoff, B. L. The Dual Chamber and vvI Implantable Defibrillator (DAvID) Trial: rationale, design, results, clinical implications and lessons for future trials. Card. Electrophysiol. Rev. 7, 468-472 (2003).
49. Muto, C. et al. Effect of right ventricular apical pacing in survivors of myocardial infarction. Pacing Clin. Electrophysiol. 32 (Suppl. 1), S173-S176 (2009).
50. Thambo, J. B. et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 110, 3766-3772 (2004).
51. varma, N. Left ventricular conduction delays induced by right ventricular apical pacing: effect of left ventricular dysfunction and bundle branch block. J. Cardiovasc. Electrophysiol. 19, 114-122 (2008).
52. Zhang, X. H. et al. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J. Cardiovasc. Electrophysiol. 19, 136-141 (2008).
53. Wilkoff, B. L. et al. The DAvID (Dual Chamber and vvI Implantable Defibrillator) II trial. J. Am. Coll. Cardiol. 53, 872-880 (2009).
54. Delnoy, P. P. et al. Long-term clinical response of cardiac resynchronization after chronic right ventricular pacing. Am. J. Cardiol. 104, 116-121 (2009).
55. Funck, r. C. et al. Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study. Europace 8, 629-635 (2006).
56. reynolds, D. W. & Murray, C. M. New concepts in physiologic cardiac pacing. Curr. Cardiol. Rep. 9, 351-357 (2007).
57. Moss, A. J. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361, 1329-1338 (2009).
58. Sweeney, M. O. et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast vT rEduces Shock ThErapies (PainFrEE rx II) trial. Circulation 111, 2898-2905 (2005).
59. Poole, J. E. et al. Prognostic importance of defibrillator shocks in patients with heart failure. N. Engl. J. Med. 359, 1009-1017 (2008).
60. Daubert, J. P. et al. Inappropriate implantable cardioverter- defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J. Am. Coll. Cardiol. 51, 1357-1365 (2008).
61. Wilkoff, B. L. et al. Design of the Primary Prevention Parameters Evaluation (PrEPArE) trial of implantable cardioverter defibrillators to reduce patient morbidity [NCT00279279]. Trials 7, 18 (2006).
62. Wilkoff, B. L. et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PrEPArE (Primary Prevention Parameters Evaluation) study. J. Am. Coll. Cardiol. 52, 541-550 (2008).
63. Wilkoff, B. L. et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIrIC trial. J. Am. Coll. Cardiol. 48, 330-339 (2006).
64. Theuns, D. A., rivero-Ayerza, M., Boersma, E. & Jordaens, L. Prevention of inappropriate therapy in implantable defibrillators: A metaanalysis of clinical trials comparing singlechamber and dual-chamber arrhythmia discrimination algorithms. Int. J. Cardiol. 125, 352-357 (2008).
65. Theuns, D. A., rivero-Ayerza, M., Goedhart, D. M., van der Perk, r. & Jordaens, L. J. Evaluation of morphology discrimination for ventricular tachycardia diagnosis in implantable cardioverterdefibrillators. Heart Rhythm 3, 1332-1338 (2006).
66. Tzeis, S., Andrikopoulos, G., Kolb, C. & vardas, P. E. Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks. Europace 10, 1256-1265 (2008).
67. Germano, J. J., reynolds, M., Essebag, v. & Josephson, M. E. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am. J. Cardiol. 97, 1255-1261 (2006).
68. Glikson, M. et al. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia. J. Cardiovasc. Electrophysiol. 15, 658-664 (2004).
69. Glikson, M. et al. Optimal combination of discriminators for differentiating ventricular from supraventricular tachycardia by dual-chamber defibrillators. J. Cardiovasc. Electrophysiol. 16, 732-739 (2005).
70. Hreybe, H. et al. relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks. Am. J. Cardiol. 97, 544-546 (2006).
71. Boriani, G., Biffi, M., Frabetti, L., Lattuca, J. J. & Branzi, A. Clinical evaluation of morphology discrimination: an algorithm for rhythm discrimination in cardioverter defibrillators. Pacing Clin. Electrophysiol. 24, 994-1001 (2001).
72. Boriani, G. et al. Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators. Pacing Clin. Electrophysiol. 25, 1357-1366 (2002).
73. Duru, F., Bauersfeld, U., rahn-Schonbeck, M. & Candinas, r. Morphology discriminator feature for enhanced ventricular tachycardia discrimination in implantable cardioverter defibrillators. Pacing Clin. Electrophysiol. 23, 1365-1374 (2000).
74. Gold, M. r. et al. A new defibrillator discrimination algorithm utilizing electrogram morphology analysis. Pacing Clin. Electrophysiol. 22, 179-182 (1999).
75. Gronefeld, G. C. Discrimination of ventricular tachycardia from supraventricular tachycardia in implantable cardioverter defibrillators by automated electrogram morphology analysis: can leads finally replace the electrophysiologist? Europace 10, 1131-1132 (2008).
76. Klein, G. J. et al. Improving SvT discrimination in single-chamber ICDs: a new electrogram morphology-based algorithm. J. Cardiovasc. Electrophysiol. 17, 1310-1319 (2006).
77. Luthje, L., vollmann, D., rosenfeld, M. & Unterberg-Buchwald, C. Electrogram configuration and detection of supraventricular tachycardias by a morphology discrimination algorithm in single chamber ICDs. Pacing Clin. Electrophysiol. 28, 555-560 (2005).
78. Toquero, J. et al. Morphology discrimination criterion wavelet improves rhythm discrimination in single-chamber implantable cardioverterdefibrillators: Spanish register of morphology discrimination criterion wavelet (rEMEDIO). Europace 11, 727-733 (2009).
79. Theuns, D. A., rivero-Ayerza, M., Goedhart, D. M., Miltenburg, M. & Jordaens, L. J. Morphology discrimination in implantable cardioverter- defibrillators: consistency of template match percentage during atrial tachyarrhythmias at different heart rates. Europace 10, 1060-1066 (2008).
80. Bansch, D. et al. The 1+1 trial: a prospective trial of a dual-versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation 110, 1022-1029 (2004).
81. Deisenhofer, I. et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J. Cardiovasc. Electrophysiol. 12, 134-142 (2001).
82. Friedman, P. A. et al. Dual-chamber versus singlechamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation 113, 2871-2879 (2006).
83. Burri, H. & Senouf, D. remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators. Europace 11, 701-709 (2009).
84. Heidbuchel, H. et al. Potential role of remote monitoring for scheduled and unscheduled evaluations of patients with an implantable defibrillator. Europace 10, 351-357 (2008). (Pubitemid 351773732)
85. res, J. C., Theuns, D. A. & Jordaens, L. The role of remote monitoring in the reduction of inappropriate implantable cardioverter defibrillator therapies. Clin. Res. Cardiol. 95 (Suppl. 3), III17-III21 (2006).
86. Schoenfeld, M. H. et al. remote monitoring of implantable cardioverter defibrillators: a prospective analysis. Pacing Clin. Electrophysiol. 27, 757-763 (2004).
87. varma N. rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T reduces routine Office Device Follow-Up Study (TrUST) study. Am. Heart J. 154, 1029-1034 (2007).
88. Neuzil, P., Taborsky, M., Holy, F. & Wallbrueck, K. Early automatic remote detection of combined lead insulation defect and ICD damage. Europace 10, 556-557 (2008).
89. ricci, r. P., Morichelli, L., Gargaro, A., Laudadio, M. T. & Santini, M. Home monitoring in patients with implantable cardiac devices: is there a potential reduction of stroke risk? results from a computer model tested through Monte Carlo simulations. J. Cardiovasc. Electrophysiol. doi:10.1111/j.1540- 81672009.01543.x.
90. Spencker, S., Coban, N., Koch, L., Schirdewan, A. & Muller, D. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. Europace 11, 483-488 (2009).